TIM3 Blockade with Hypomethylating Therapy Restores NK Cell and Cytotoxic CD4+ T-cell Activity in Patients with AML or MDS.
Jani Huuhtanen, Sofia Forstén, Brittany Ford et al.
✦ AI-curated · Sources linked
In 30 seconds
This phase Ib clinical trial examined immune changes in patients with AML or MDS treated with anti-TIM3 sabatolimab plus decitabine. Analyses included 14 patients, with single-cell RNA and T-cell receptor sequencing in six and functional coculture assays. Treatment was associated with expansion of cytotoxic natural killer cell subsets and stronger type I interferon signaling; responders also showed greater expansion of cytotoxic CD4+ T cells and B cells. One patient with preexisting CD4+ T-cell large granular lymphocyte leukemia achieved a complete response lasting 23 months. The findings suggest immune activation distinct from that associated with anti-PD-1 or anti-CTLA4 therapy.
Key findings
- Treatment expanded cytotoxic NK-cell subsets and enhanced type I interferon signaling.
- Fewer than 1% of bone marrow CD8+ T cells showed a canonical exhaustion phenotype.
- Responders had greater expansion of cytotoxic CD4+ T cells and B cells.
- A patient with preexisting CD4+ T-cell large granular lymphocyte leukemia achieved a complete response lasting 23 months.
Why it matters
The study characterizes immune changes accompanying TIM3 blockade with decitabine in AML and MDS, suggesting that NK cells and cytotoxic CD4+ T cells may be prominent components of the response. This broadens understanding of potential immune targets in these diseases, while the small, exploratory clinical dataset does not establish which patients will benefit or the regimen’s comparative efficacy.
What to keep in mind
The phase Ib study included 14 patients, and single-cell sequencing was performed in six; the immune analyses are therefore based on a small cohort.